C2N Diagnostics is a specialty diagnostics company focused on developing and commercializing tests for Alzheimer’s disease and other forms of neurodegeneration. Guided by its “Clarity Through Innovation” approach, the company combines neurological expertise with proprietary, high-resolution liquid chromatography–tandem mass spectrometry to create biomarker products for clinical care, research, and clinical trials. Its services include clinical diagnostics and bioanalytical laboratory services, supporting healthcare professionals and researchers working to improve brain health.

C2N’s Precivity blood tests are intended to help assess brain amyloid pathology in people experiencing cognitive impairment. PrecivityAD and PrecivityAD2 support Alzheimer’s disease evaluations and may inform medical management and treatment decisions; Precivity-ApoE provides information about apolipoprotein E allele status when relevant to care. The tests are ordered by healthcare professionals, with specific intended-use populations varying by test. C2N’s products can also support treatment monitoring, clinical-trial quality and efficiency, and research into disease mechanisms, treatment targets, and population health. Through its diagnostic development and laboratory capabilities, C2N aims to make Alzheimer’s assessment more accessible and help improve patient care.